## 2 Case Presentation
\begin{table}
\begin{tabular}{c c c c c c c c c c c c c} \hline  & & \multicolumn{4}{c}{**DEPP Period**} & \multicolumn{4}{c}{**Outside DEPP Period**} & \multicolumn{4}{c}{**Difference between Averages**} \\ \hline  & **I** & **II** & **III** & **IV** & **V** & **VI** & **Pre-DFPP** & **Post-DEPP** & **Mean \(\pm\) SD** & **Mean \(\pm\) SD** & **Mean \(\pm\) SD** & **\(p\)** \\  & **I** & **II** & **III** & **IV** & **V** & **VI** & **Period** & **Post-DEPP** & **Mean \(\pm\) SD** & **Mean \(\pm\) SD** & **mean \(\pm\) SD** & **\(p\)** \\  & & & & & & & & & & & 95\% IC** & 95\% IC & 95\% IC \\ \hline
**C3** & 83.7 & 62.3 & 60.0 & 85.3 & 67.1 & 56.1 & 110.0 & 120.0 & **62.3 \(\pm\) 83.7** & **110.0 \(\pm\) 120.0** & **0.006** \\
**C4** & 18.3 & 14.2 & 15.0 & 18.4 & 15.7 & 13.9 & 19.0 & 21.0 & **15.9 \(\pm\) 1.9** & **20.0 \(\pm\) 1.4** & **0.002** \\  & & & & & & & & & 14.2 \(\pm\) 18.3** & 19.0 \(\pm\) 21.0** & **0.002** \\
**FGG** & 246.0 & 175.0 & 193.0 & 350.0 & 241.0 & 224.0 & 407.0 & 400.0 & **238.1 \(\pm\) 61.3** & **403.5 \(\pm\) 4.9** & **0.011** \\
**IgG** & 506.0 & 357.0 & 339.0 & 376.0 & 295.0 & 257.0 & 898.0 & 900.0 & **355.0 \(\pm\) 85.6** & **899.0 \(\pm\) 1.4** & **0.000** \\  & & & & & & & & 296.0 \(\pm\) 230.4** & **898.0 \(\pm\) 900.0** & **0.00** \\
**IgM** & 45.0 & 23.0 & 18.0 & 25.0 & 21.0 & 18.0 & 67.0 & 75.0 & **25.0 \(\pm\) 10.17** & 66.0 \(\pm\) 1.4** & **0.002** \\  & & & & & & & & & 19.3 \(\pm\) 34.6** & 65.0 \(\pm\) 67.0 & **0.002** \\  & & & & & & & & & **48.8 \(\pm\) 8.95** & 96.5 \(\pm\) 2.1** & **0.000** \\
**IgA** & 63.0 & 42.0 & 40.0 & 56.0 & 48.0 & 44.0 & 98.0 & 95.0 & **42.5 \(\pm\) 56.3** & **95.0 \(\pm\) 98.0** & **0.000** \\
**IgE** & 33.0 & 23.0 & 28.0 & 35.0 & 29.0 & 36.0 & 23.0 & 28.0 & **30.7 \(\pm\) 4.9** & **25.5 \(\pm\) 3.5** & **0.000** \\  & & & & & & & & 26.6 \(\pm\) 34.3 & 23.0 \(\pm\) 28.0 & **n.s.** \\
**ALB** & 3270.0 & 2720.0 & 2800.0 & 2540.0 & 2440.0 & 2090.0 & 3050.0 & 3000.0 & **2643.3 \(\pm\) 395.3** & **3025 \(\pm\) 395.3** & **n.s.** \\  & & & & & & & & & **2345.0 \(\pm\) 2967.1** & 3000.0 \(\pm\) 3050.0 & **n.s.** \\ \hline \end{tabular}
\end{table} 
Table 1: All values of albumin (ALB), immunoglobulin G (IgG), A (IgA), M (IgM), E ((gE), gamma-fibrinogen (FGG), and the C3/C4 components of the complement measured immediately after each DEPP session performed every other day, except for session IV, in which the blood sample was executed just before treatment. Measurements of ALB, IgG, IgA, IgM, FGG, and C3/C4 are shown in mg/dL, and IgG is shown in IU/mL. Differences between means of species’ values measured during and outside DEPP period, with related \(p\) values, are shown in bold. Due to the molecular filtering activity of the second mesh, a modest nonsignificant reduction in serum albumin concentration was found. Thus, an albuminated replacement solution was mandatorily administrated after each DFPP session. Other routine clinical assessments were in the normal range of values during the DFPP treatment period. From a clinical point of view, we observed an initial functional improvement right after the second DFPP section that increasingly continued during the treatment period. The sequence of the decline of symptoms was as follows: first, ataxia; second, spasticity; third, weakness. At the time of discharge from the ward, EDSS = 3.0 and a residual slight lower extremity weakness in comparison to the baseline conditions was detected. We noted a plateau of clinical improvement corresponding to the time-period of DFPP, with an extending tail over the following month of neurological intensive rehabilitation. This favorable clinical outcome was consistent with a similar safety profile. The main adverse event was a slight hypotension at the end of some procedures. The control MRI performed before the department discharge showed detectable reduction in the volume of cervical lesions, as depicted in Figure 1B, but a stable brain lesion load (Figure 1D).